SDB-005

Edit links
Source: Wikipedia, the free encyclopedia.
SDB-005
Legal status
Legal status
Identifiers
  • Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate
JSmol)
  • CCCCCN1N=C(C(=O)OC2=CC=CC3=C2C=CC=C3)C2=C1C=CC=C2
  • InChI=1S/C23H22N2O2/c1-2-3-8-16-25-20-14-7-6-13-19(20)22(24-25)23(26)27-21-15-9-11-17-10-4-5-12-18(17)21/h4-7,9-15H,2-3,8,16H2,1H3
  • Key:JBVNFKZVDLFOAY-UHFFFAOYSA-N

SDB-005 is an

8-hydroxyquinoline has also been replaced with a naphthalene
group.

The code number SDB-005 was originally used for a different compound, the N-phenyl instead of N-benzyl analogue of

CB2 receptor (Ki = 140 nM).[2]

Original, non designer drug SDB-005

However, SDB-005 was subsequently used as the name for the indazole-3-carboxylate compound mentioned above when it was sold in Europe as a

EMCDDA synthetic drug database under this name.[3]
Consequently, there are now two distinct, yet fairly closely related cannabinoid compounds, which may both be referred to under the code SDB-005.

See also

References

  1. ^ "SDB-005". Cayman Chemical. Retrieved 27 June 2015.
  2. PMID 23551277
    .
  3. ^ EWS_EU: Neue Psychoaktive Substanzen, April 2015
Retrieved from "https://en.wikipedia.org/w/index.php?title=SDB-005&oldid=1109039484"